David Gobel  David Gobel (born 1952 in Baltimore, Maryland) is an American philanthropist, entrepreneur, inventor, and futurist. He is co-founder and CEO of the Methuselah Foundation, CEO of the Methuselah Fund, and the first to publicly advance the idea of longevity escape velocity or actuarial escape velocity. David Gobel is co-founder and Chief Executive Officer of the Methuselah Foundation, a medical charity based in Springfield, VA. To date, Methuselah has given more than $4 million to support research and development in regenerative medicine. With co-founder Aubrey de Grey, Gobel established Methuselah in 2003 in order to "shed light on the processes of aging and find ways to extend healthy life." Through Methuselah, Gobel, and de Grey established research programs focused on advanced human bioremedial biology at Rice University and Arizona State University—the world's first use of environmental remediation techniques to be directed at reversing "pollution" in human cells. Methuselah has also provided funding and strategic support to companies developing breakthrough technologies and clinical interventions in regenerative medicine. These companies include: Organovo (NYSE: ONVO), a pioneer in 3D tissue printing; Silverstone Solutions (acquired by BiologicTx in 2013), a maker of kidney-matching software that has enabled hospitals and transplant organizations to more quickly and accurately pair patients with compatible donors; Oisin Biotechnologies, a creator of an intervention to remove harmful senescent cells ("zombie" cells) based on their DNA expression; and Leucadia Therapeutics, a company developing a therapy to address Alzheimer's disease by restoring the flow of cerebrospinal fluid across the cribriform plate in the nasal cavity. In 2013, Methuselah announced a new $500,000 partnership with Organovo to place 3D bioprinters in several U.S. university research labs as springboards for cutting-edge research. In the same year, Methuselah launched a second prize series, entitled New Organ, to accelerate solutions to the global organ shortage. The first prize in this series, the $1 million New Organ Liver Prize, "will award $1,000,000 to the first team that creates a bioengineered replacement for the native liver of a large mammal, enabling it to recover in the absence of native function and survive three months with a normal lifestyle." In 2016, NASA announced the Vascular Tissue Challenge in partnership with Methuselah Foundation.